Methods of reducing risk of preterm birth
This disclosure generally relates to methods for reducing the risk of preterm birth in a pregnant human female patient that include subcutaneous administration of HPC. The disclosure relates in part to the discovery that subcutaneous administration of HPC is actually feasible and can result in sufficient plasma levels of HPC in pregnant patients that can reduce the risk of preterm birth.
1. A method of reducing the risk of preterm birth in a pregnant human patient, comprising: subcutaneously administering to the posterior portion of the upper arm of a pregnant human patient a 1.1 mL dose comprising a pharmaceutically acceptable non-aqueous formulation comprising 275 mg 17-α hydroxyprogesterone caproate,
wherein the subcutaneous administration of hydroxyprogesterone caproate provides in the patient an AUC 0-t of between about 120% to about 88% compared to an AUC 0-t of the patient administered the same dosage amount of hydroxyprogesterone caproate intramuscularly, and
wherein the dose is administered weekly, beginning about 16 weeks or later of gestation.
2. The method of claim 1 , wherein the subcutaneous administration of hydroxyprogesterone caproate provides in the patient an AUC 0-t of about 104% compared to an AUC 0-t of the patient administered the same dosage amount of hydroxyprogesterone caproate intramuscularly.
3. The method of claim 1 , wherein the dose is subcutaneously administered beginning between about 16 weeks, zero days of gestation to about 20 weeks, six days of gestation, and continued until about 37 weeks of gestation or until delivery, whichever occurs first.
4. The method of claim 1 , wherein the pregnant human patient has a singleton pregnancy.
5. The method of claim 4 , wherein the pregnant human patient has a history of singleton spontaneous preterm birth.
6. The method of claim 1 , wherein the pharmaceutically acceptable non-aqueous liquid formulation further comprises castor oil.
7. The method of claim 6 , wherein the pharmaceutically acceptable non-aqueous liquid formulation further comprises benzyl benzoate.
8. The method of claim 1 , wherein the pharmaceutically acceptable non-aqueous liquid formulation consists essentially of 17-α hydroxyprogesterone caproate, castor oil, and benzyl benzoate.
9. A method of reducing the risk of preterm birth in a pregnant human patient, comprising: subcutaneously administering to the posterior portion of the upper arm of a pregnant human patient a 1.1 mL dose comprising a pharmaceutically acceptable non-aqueous formulation comprising 275 mg 17-α hydroxyprogesterone caproate,
wherein the subcutaneous administration of hydroxyprogesterone caproate provides in the patient at least one of:
a C max of about between about 96% to about 157% compared to a C max of the patient administered the same dosage amount of hydroxyprogesterone caproate intramuscularly;
an AUC 0-t of between about 120% to about 88% compared to an AUC 0-t of the patient administered the same dosage amount of hydroxyprogesterone caproate intramuscularly;
a C max of about 8 ng/mL; and
an AUC of about 2,770 hr ·ng/mL to about 2,900 hr ng/mL, and wherein the dose is administered weekly, beginning about 16 weeks or later of gestation.
10. The method of claim 9 , wherein the subcutaneous administration of hydroxyprogesterone caproate provides in the patient a C max of about between about 96% to about 157% compared to a C max of the patient administered the same dosage amount of hydroxyprogesterone caproate intramuscularly.
11. The method of claim 9 , wherein the subcutaneous administration of hydroxyprogesterone caproate provides in the patient an AUC 0-t of between about 120% to about 88% compared to an AUC 0-t of the patient administered the same dosage amount of hydroxyprogesterone caproate intramuscularly.
12. The method of claim 9 , wherein the subcutaneous administration of hydroxyprogesterone caproate provides in the patient a C max of about 8 ng/mL.
13. The method of claim 9 , wherein the subcutaneous administration of hydroxyprogesterone caproate provides in the patient an AUC of about 2,770 hr ·ng/mL to about 2,900 hr ng/mL.
14. A method of reducing the risk of preterm birth in a pregnant human patient, comprising: subcutaneously administering to the posterior portion of the upper arm of a pregnant human patient a 1.1 mL dose comprising a pharmaceutically acceptable non-aqueous formulation comprising 275 mg 17-α hydroxyprogesterone caproate,
wherein between about 24 to 48 hours after administration of the hydroxyprogesterone caproate dose the patient has a mean plasma concentration of about 5 ng/mL to about 12 ng/mL, and
wherein the dose is administered weekly, beginning about 16 weeks or later of gestation.
15. The method of claim 14 , wherein between about 24 to 48 hours after administration of the hydroxyprogesterone caproate dose the patient has a mean plasma concentration of between about 6 ng/mL to 8 ng/mL.
16. A method of reducing the risk of preterm birth in a pregnant human patient, comprising: subcutaneously administering to the posterior portion of the upper arm of a pregnant human patient a 1.1 mL dose comprising a pharmaceutically acceptable non-aqueous formulation comprising 275 mg 17-α hydroxyprogesterone caproate,
wherein the subcutaneous administration of hydroxyprogesterone caproate provides in the patient a T max of between about 18 hours to about 168 hours.
17. The method of claim 16 , wherein the subcutaneous administration of hydroxyprogesterone caproate provides in the patient a T max of about 24 hours.
18. The method of claim 1 , wherein the dosage is administered by a healthcare professional.
19. The method of claim 9 , wherein the dosage is administered by a healthcare professional.
20. The method of claim 14 , wherein the dosage is administered by a healthcare professional.
21. The method of claim 16 , wherein the dosage is administered by a healthcare professional.